PLGA-based long-acting injectable (LAI) formulations
Journal of Controlled Release · 2025
DOI: 10.1016/j.jconrel.2025.113758 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2025. Verfasst von Kinam Park. Beteiligte Einrichtung: Purdue University, Weldon School of Biomedical Engineering and Department of Industrial and Molecular Pharmaceutics, West Lafayette, IN 47907, USA; A…. Hauptthemen laut MEDLINE: Polylactic Acid-Polyglycolic Acid Copolymer, Delayed-Action Preparations. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 219 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse, Purdue University.
Abstract (Originalsprache)
Long-acting injectable (LAI) formulations, which deliver drugs over weeks or months, have been in use for more than three decades. Most clinically approved LAI products are formulated using poly(lactide-co-glycolide) (PLGA) polymers. Historically, the development of PLGA-based LAI formulations has relied predominantly on trial-and-error methods, primarily due to a limited understanding of the complex factors involved in LAI formulations and insufficient analytical techniques available for characterizing individual PLGA polymers of the prepared formulations. This article offers a personal perspective on recent advancements in characterization methods for PLGA polymers within final formulations, i.e., products, as well as enhanced insights into the drug release mechanisms associated with LAI products. With a deeper understanding of PLGA polymer properties and drug release mechanisms, the formulation development process can transition from traditional trial-and-error practices to a more systematic Quality by Design (QbD) approach. Additionally, this article explores the emerging role of artificial intelligence (AI) in formulation science and its potential, when applied carefully, to enhance the future development of PLGA-based LAI formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Purdue University, Weldon School of Biomedical Engineering and Department of Industrial and Molecular Pharmaceutics, West Lafayette, IN 47907, USA; Akina, Inc., 3495 Kent Avenue, West Lafayette, IN 47906, USA. Electroni…
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
- Purdue University
- Center for Drug Evaluation and Research
- Billings Arts Association
- US Food and Drug Administration
Zitieren
APA
Park, K. (2025). PLGA-based long-acting injectable (LAI) formulations. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2025.113758
Vancouver
Park K. PLGA-based long-acting injectable (LAI) formulations. Journal of Controlled Release. 2025. doi:10.1016/j.jconrel.2025.113758
BibTeX
@article{Park2025,
author = {Park, Kinam},
title = {PLGA-based long-acting injectable (LAI) formulations},
journal = {Journal of Controlled Release},
year = {2025},
doi = {10.1016/j.jconrel.2025.113758}
}
EUVIMED